Donald W. Mann

671 total citations
18 papers, 408 citations indexed

About

Donald W. Mann is a scholar working on Molecular Biology, Immunology and Pharmacology. According to data from OpenAlex, Donald W. Mann has authored 18 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Immunology and 4 papers in Pharmacology. Recurrent topics in Donald W. Mann's work include Inflammatory mediators and NSAID effects (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Donald W. Mann is often cited by papers focused on Inflammatory mediators and NSAID effects (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Donald W. Mann collaborates with scholars based in United States, Philippines and Ukraine. Donald W. Mann's co-authors include Andrea J. Gonzales, Mark J. Mitton‐Fry, Gregory J. Fici, James Forman, Leroy Hood, Iwona Stroynowski, D.C. German, Randall Kiser, Parkhurst A. Shore and Angela J. Okragly and has published in prestigious journals such as The Journal of Experimental Medicine, The Journal of Immunology and Epilepsia.

In The Last Decade

Donald W. Mann

17 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Donald W. Mann United States 12 122 79 77 56 55 18 408
J J Guillosson France 11 136 1.1× 80 1.0× 60 0.8× 6 0.1× 102 1.9× 19 456
Philip W. Askenase United States 16 431 3.5× 207 2.6× 92 1.2× 15 0.3× 104 1.9× 34 737
Hasna Baidouri United States 13 134 1.1× 149 1.9× 26 0.3× 21 0.4× 14 0.3× 21 556
Koji Kawano Japan 14 54 0.4× 152 1.9× 74 1.0× 10 0.2× 70 1.3× 25 386
A.L. de Weck Switzerland 12 168 1.4× 43 0.5× 89 1.2× 13 0.2× 225 4.1× 38 522
Murli Manohar United States 13 158 1.3× 82 1.0× 10 0.1× 34 0.6× 11 0.2× 22 387
R. Sack United States 7 46 0.4× 110 1.4× 49 0.6× 31 0.6× 50 0.9× 17 639
M. Radermecker Belgium 13 116 1.0× 70 0.9× 20 0.3× 7 0.1× 66 1.2× 39 418
Ronald W. Gillette United States 12 246 2.0× 117 1.5× 54 0.7× 13 0.2× 10 0.2× 53 512
Helen Kado‐Fong United States 10 75 0.6× 139 1.8× 10 0.1× 6 0.1× 49 0.9× 15 400

Countries citing papers authored by Donald W. Mann

Since Specialization
Citations

This map shows the geographic impact of Donald W. Mann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald W. Mann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald W. Mann more than expected).

Fields of papers citing papers by Donald W. Mann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald W. Mann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald W. Mann. The network helps show where Donald W. Mann may publish in the future.

Co-authorship network of co-authors of Donald W. Mann

This figure shows the co-authorship network connecting the top 25 collaborators of Donald W. Mann. A scholar is included among the top collaborators of Donald W. Mann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald W. Mann. Donald W. Mann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Mann, Donald W., Jeremias Antinew, Lloyd Knapp, et al.. (2020). Pregabalin adjunctive therapy for focal onset seizures in children 1 month to <4 years of age: A double‐blind, placebo‐controlled, video‐electroencephalographic trial. Epilepsia. 61(4). 617–626. 15 indexed citations
2.
Gonzales, Andrea J., et al.. (2014). Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Journal of Veterinary Pharmacology and Therapeutics. 37(4). 317–324. 167 indexed citations
3.
Mann, Donald W., Jing Liu, Marci L. Chew, et al.. (2014). Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: A phase 1, randomized controlled study. Epilepsia. 55(12). 1934–1943. 22 indexed citations
4.
Sakya, Subas M., Andrei Shavnya, Hengmiao Cheng, et al.. (2007). Comparative structure–activity relationship studies of 1-(5-methylsulfonylpyrid-2-yl)-5-alkyl and (hetero)aryl triazoles and pyrazoles in canine COX inhibition. Bioorganic & Medicinal Chemistry Letters. 18(3). 1042–1045. 10 indexed citations
5.
Sakya, Subas M., Xinjun Hou, Martha L. Minich, et al.. (2006). 5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part III: Molecular modeling studies on binding contribution of 1-(5-methylsulfonyl)pyrid-2-yl and 4-nitrile. Bioorganic & Medicinal Chemistry Letters. 17(4). 1067–1072. 28 indexed citations
6.
Li, Jin, Michael P. Lynch, Subas M. Sakya, et al.. (2004). In vitro and in vivo profile of 2-(3-di-fluoromethyl-5-phenylpyrazol-1-yl)-5-methanesulfonylpyridine, a potent, selective, and orally active canine COX-2 inhibitor. Bioorganic & Medicinal Chemistry. 13(5). 1805–1809. 8 indexed citations
7.
Okragly, Angela J., et al.. (1996). Bovine gamma/delta T-cell proliferation is associated with self-derived molecules constitutively expressed in vivo on mononuclear phagocytes.. PubMed. 87(1). 71–9. 19 indexed citations
8.
Johnson, Robert A., Donald W. Mann, & Luc Soenen. (1994). Optimal EMS Currency Baskets versus the ECU. Multinational Business Review. 2(2). 44. 1 indexed citations
9.
Aldrich, Carla J., Donald W. Mann, Michael I. Nishimura, et al.. (1991). The Q7 alpha 3 domain alters T cell recognition of class I antigens. The Journal of Immunology. 146(9). 3082–3090. 19 indexed citations
10.
Mann, Donald W., Iwona Stroynowski, Leroy Hood, & J Forman. (1989). An H-2Ld hybrid molecule with a Qa-2 alpha-3 domain and phosphatidyl-inositol anchor is not recognized by H-2Ld-specific cytotoxic T lymphocytes.. The Journal of Immunology. 142(1). 318–322. 9 indexed citations
11.
12.
Mann, Donald W., E McLaughlin-Taylor, R. Bruce Wallace, & James Forman. (1988). An immunodominant epitope present in multiple class I MHC molecules and recognized by cytotoxic T lymphocytes.. The Journal of Experimental Medicine. 168(1). 307–324. 11 indexed citations
13.
Mann, Donald W. & James Forman. (1988). Recognition by cytotoxic T lymphocytes of Qa-2 antigens. Sensitivity of Qa-2 molecules to phosphatidylinositol-specific phospholipase C.. The Journal of Immunology. 141(6). 1813–1818. 14 indexed citations
14.
Koeller, David M., Ronald Lieberman, Jun‐ichi Miyazaki, et al.. (1987). Introduction of H-2Dd determinants into the H-2Ld antigen by site-directed mutagenesis.. The Journal of Experimental Medicine. 166(3). 744–760. 11 indexed citations
15.
Mann, Donald W., Iwona Stroynowski, Leroy Hood, & James Forman. (1987). Cytotoxic T lymphocytes from mice with soluble class I Q10 molecules in their serum are not tolerant to membrane-bound Q10.. The Journal of Immunology. 138(1). 240–245. 23 indexed citations
16.
Mann, Donald W., Gerald Sonnenfeld, & Joan Stein‐Streilein. (1985). Pulmonary Compartmentalization of Interferon and Natural Killer Cell Activity. Experimental Biology and Medicine. 180(2). 224–230. 11 indexed citations
17.
Mann, Donald W.. (1981). Fewer People for a Better World: A Plea for Negative Population Growth. Environmental Conservation. 8(4). 260–261. 1 indexed citations
18.
German, D.C., et al.. (1979). Dopaminergic neuronal responses to a non-amphetamine CNS stimulant. Journal of Neural Transmission. 44(1-2). 39–49. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J J Guillosson Breakdown of academic impact, for papers by Philip W. Askenase Breakdown of academic impact, for papers by Hasna Baidouri Breakdown of academic impact, for papers by Koji Kawano Breakdown of academic impact, for papers by A.L. de Weck Breakdown of academic impact, for papers by Murli Manohar Breakdown of academic impact, for papers by R. Sack Breakdown of academic impact, for papers by M. Radermecker Breakdown of academic impact, for papers by Ronald W. Gillette Breakdown of academic impact, for papers by Helen Kado‐Fong
Rankless by CCL
2026